8-K: Banzai Secures $2.5M in Convertible Note Financing

Banzai International, Inc. completed an additional closing of its private placement, issuing $2.5 million in senior secured convertible notes and warrants to an institutional investor.

Summary

• Banzai International, Inc. (BNZI) completed an additional closing of its private placement on October 8, 2025, issuing a Senior Secured Convertible Note with an original principal amount of $2,500,000 (the "October Note") and warrants to purchase up to 200,000 shares of Common Stock (the "October Warrants").
• The October Note was issued with a 10.0% Original Issue Discount (OID) and accrues interest at a rate of 10.0% per annum, compounding monthly, with a maturity date of October 8, 2026.
• The initial conversion price for the October Note is $2.50 per share, subject to adjustment, with a floor price of $0.62.
• The October Warrants have an exercise price of $2.50 per share, are exercisable immediately, and have a three-year term.
• This October Closing follows previous closings on June 30, 2025 ($2,200,000 Initial Note and 671,243 warrants) and August 19, 2025 ($2,200,000 August Note and 126,107 warrants), bringing the total principal amount of notes issued to $6,900,000 out of a maximum of $11,000,000 under the Securities Purchase Agreement.
• The net proceeds to the Company from the October Closing were approximately $2.01 million, after deducting financial advisory fees and estimated offering expenses.
• Rodman & Renshaw LLC, as the exclusive financial advisor, received a cash fee of 7% of the gross proceeds, a 1.0% management fee, and warrants to purchase 63,636 shares of Common Stock at an exercise price of $3.13 per share.
• All shares underlying the October Note and Warrants are registered under a Form S-3 registration statement (File No. 333-289099).
• The Company is required to make monthly installment payments of $183,333.33 towards the principal balance of the Notes, plus accrued interest, starting from August 1, 2025 (or the effective date of the initial Registration Statement), payable in cash or, under certain conditions, in shares of Common Stock at the Company's option.
• In the event of default, the investor can require redemption of the notes at a 15% premium, and the interest rate increases to 18% per annum.

Sentiment

Score: 3

Explanation: While the Company successfully raised capital, the terms of the financing are highly dilutive and expensive, reflecting a challenging financing environment or a high perceived risk by investors. The significant OID, high interest rate, low conversion/exercise prices, and substantial advisor fees suggest a less favorable outcome for existing shareholders, despite the immediate liquidity provided.

Positives

• The Company successfully secured an additional $2.5 million in capital, providing funds for general corporate purposes and working capital.
• The notes are senior secured, offering a level of security to the investor, which can be attractive for securing financing.
• The shares underlying the notes and warrants are registered, facilitating their resale by the investor.
• The financing is part of a larger facility, indicating ongoing access to capital up to $11 million.

Negatives

• The October Note was issued with a significant 10.0% Original Issue Discount (OID), reducing the immediate cash proceeds to the Company.
• The annual interest rate of 10.0% is high, and the default rate of 18% is punitive, indicating a high cost of capital for the Company.
• The initial conversion price of $2.50 and warrant exercise price of $2.50 are relatively low, posing a substantial risk of dilution for existing shareholders.
• The Company incurred significant financial advisory fees, including a 7% cash fee, a 1.0% management fee, and additional warrants, further increasing the cost of this capital raise.
• Restrictive covenants limit the Company's ability to incur other indebtedness, create liens, make restricted payments, pay cash dividends, or transfer assets, potentially hindering future operational and financial flexibility.
• The Company is restricted from certain capital market activities, including other Variable Rate Transactions, for 180 days post-October Closing or until no Notes remain outstanding.

Risks

• **Dilution Risk**: Significant potential for dilution of existing shareholders due to the conversion of notes and exercise of warrants at relatively low prices.
• **High Cost of Capital**: The 10% OID and 10% annual interest rate (18% default rate) represent a high cost of capital, which could strain the Company's financial resources and impact profitability.
• **Event of Default**: Numerous triggers for an Event of Default, including failure to file/maintain registration statements, trading suspensions, failure to deliver shares, failure to pay amounts due, and breaches of covenants, could lead to accelerated redemption at a premium.
• **Authorized Share Failure**: The Company must maintain sufficient authorized and unreserved shares for conversion and exercise; failure to do so could result in cash redemption obligations.
• **Market Price Volatility**: The conversion and exercise prices are subject to adjustments based on market prices, and a declining stock price could lead to further dilution or increased cash obligations for the Company.
• **Restrictive Covenants**: Covenants limit the Company's ability to incur additional debt, grant liens, make certain payments, or change its business, potentially restricting strategic flexibility.
• **Liquidity Risk**: The Company's ability to meet monthly installment payments and potential redemption obligations (especially upon an Event of Default or Change of Control) depends on its cash flow and access to further financing.

Future Outlook

The Company intends to use the net proceeds from the October Closing for general corporate purposes and working capital. It is subject to restrictions on issuing other notes or securities that would cause a breach under the existing notes or warrants, and on engaging in Variable Rate Transactions (with exceptions) until 180 days after the October Closing or until no notes remain outstanding.

Industry Context

This financing structure, involving senior secured convertible notes with a significant original issue discount, high interest rate, and warrants, is characteristic of capital raises for smaller, growth-stage companies or those facing challenging market conditions. Such terms often reflect a higher perceived risk by investors and a greater cost of capital for the issuer, common when traditional debt or less dilutive equity options are unavailable or less attractive. The use of proceeds for general corporate purposes and working capital suggests a need for operational funding rather than specific growth initiatives.

Comparison to Industry Standards

• The 10% interest rate and 10% OID are substantially higher than typical rates for established, investment-grade companies, aligning with the risk profile of a smaller, potentially less mature public company like Banzai International, Inc.
• The conversion price of $2.50 and warrant exercise price of $2.50 are at a level that suggests the financing was structured to be attractive to the institutional investor, potentially leading to significant dilution for existing shareholders if the stock price rises above these levels.
• The beneficial ownership limitation of 4.99% (or 9.99% with notice) is a standard provision for institutional investors to avoid triggering certain SEC reporting requirements (e.g., Schedule 13D) and is common in such private placements.
• The redemption premiums (15% for Event of Default, 130% for Change of Control) are robust protective measures for the investor, typical in high-yield or distressed convertible debt instruments.
• The financial advisor fees (7% cash fee, 1% management fee, and additional warrants) are on the higher end of industry norms for private placements, reflecting the complexity, size, and potentially the perceived risk of the transaction for the advisor.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Face significant potential for dilution from the conversion of notes and exercise of warrants at relatively low prices. The high cost of capital could negatively impact future earnings per share and overall shareholder value.
• **Creditors**: The institutional investor holding the senior secured convertible notes gains a priority position over other unsecured creditors in the event of financial distress or liquidation.
• **Company Operations**: The capital infusion provides necessary working capital and funds for general corporate purposes, supporting ongoing operations and potentially enabling short-term growth initiatives, but at a high cost.
• **Management**: Must adhere to restrictive covenants that limit financial and operational flexibility, requiring careful strategic planning and execution to avoid triggering events of default.

Next Steps

• The Company will utilize the net proceeds from the October Closing for general corporate purposes and working capital.
• Monthly installment payments of $183,333.33 towards principal, plus accrued interest, will continue for the outstanding notes.
• The Company must ensure it maintains sufficient authorized and unreserved shares of Common Stock to satisfy potential conversions and warrant exercises.
• The Company is subject to restrictions on certain capital market activities, including Variable Rate Transactions, until at least 180 days after the October Closing or until no Notes remain outstanding.

Key Dates

Recommendation

The terms of this financing, including a 10% Original Issue Discount, a 10% annual interest rate, and a low conversion price of $2.50 (with a $0.62 floor), are highly unfavorable and indicative of a company in a precarious financial position or with limited financing options. The significant dilution potential from the convertible notes and warrants, coupled with substantial fees to the financial advisor, will likely place considerable pressure on the stock price. While the capital infusion provides short-term liquidity, the long-term cost and dilutive impact suggest a negative outlook for existing shareholders. The restrictive covenants also limit the company's financial flexibility, making a 'sell' recommendation appropriate for seasoned investors.

Keywords

Banzai International, BNZI, convertible note, private placement, warrants, financing, capital raise, dilution, secured debt, corporate finance, SEC filing, 8-K